2019
DOI: 10.1200/jco.2019.37.15_suppl.9045
|View full text |Cite
|
Sign up to set email alerts
|

Brigatinib in pretreated patients with ALK-positive advanced NSCLC.

Abstract: 9045 Background: Brigatinib is a next-generation ALK inhibitor initially developed in pre-treated ALK+ NSCLC. Data on the efficacy of brigatinib in real world remain rare. Methods: This retrospective multicentric study analyzed ALK-+ advanced NSCLC patients pretreated with at least two tyrosine-kinase inhibitors, including crizotinib, and enrolled in the brigatinib French early access program. The primary endpoint was investigator-assessed progression-free survival (PFS). Results: 104 patients were included (… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
5
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(5 citation statements)
references
References 0 publications
0
5
0
Order By: Relevance
“…Previous reports have demonstrated real-world effectiveness of brigatinib. The BRIGALK study was a retrospective analysis of 104 patients with ALK+ NSCLC admitted into the brigatinib EAP in France from 1 September 2016 to 1 January 2018 [23]. Among patients pretreated with ≥2 ALK TKIs, mPFS was 6.6 months (95% CI: 4.8-9.9) with a median OS of 17.2 months (95% CI: 11.0-not reached) [23].…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…Previous reports have demonstrated real-world effectiveness of brigatinib. The BRIGALK study was a retrospective analysis of 104 patients with ALK+ NSCLC admitted into the brigatinib EAP in France from 1 September 2016 to 1 January 2018 [23]. Among patients pretreated with ≥2 ALK TKIs, mPFS was 6.6 months (95% CI: 4.8-9.9) with a median OS of 17.2 months (95% CI: 11.0-not reached) [23].…”
Section: Discussionmentioning
confidence: 99%
“…The BRIGALK study was a retrospective analysis of 104 patients with ALK+ NSCLC admitted into the brigatinib EAP in France from 1 September 2016 to 1 January 2018 [23]. Among patients pretreated with ≥2 ALK TKIs, mPFS was 6.6 months (95% CI: 4.8-9.9) with a median OS of 17.2 months (95% CI: 11.0-not reached) [23]. At brigatinib initiation, these patients had a poorer PS (PS 0-1: 59.1%, PS ≥2: 40.9%) than those in the present study (PS 0-1: 85.9%, PS 2: 8.1%) [23].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Both ceritinib and brigatinib have been evaluated in small numbers of patients following failure of at least one second-generation ALK inhibitor (such as alectinib), and have shown ORRs ranging from 17% to 50%. [9][10][11][12][13] Most patients with advanced ALK-positive NSCLC will receive chemotherapy at some point during their disease course, especially once available TKI options are exhausted. In two separate phase III trials, PROFILE 1014 and ASCEND-4, platinum (PT)/pemetrexed (pem) chemotherapy showed efficacy in newly diagnosed patients with advanced ALK-positive NSCLC, with a median PFS of 7.0 and 8.1 months, respectively.…”
Section: Introductionmentioning
confidence: 99%